Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.21.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 68,963 $ 28,193
Marketable securities 44,825 118,130
Accrued interest receivable 69 277
Prepaid research and development expenses 5,071 2,221
Other prepaid expenses and current assets 648 2,764
Total current assets 119,576 151,585
Property and equipment, net 1,341 1,761
Operating lease right-of-use asset 264 272
Other assets 1,721 207
Total assets 122,902 153,825
Current liabilities:    
Accounts payable 764 231
Accrued research and development expenses 6,451 4,698
Other accrued liabilities 4,526 4,928
Total current liabilities 11,741 9,857
Development financing liability 23,259 0
Long-term portion of operating lease liability 844 1,262
Total liabilities 35,844 11,119
Commitments and contingencies
Stockholders' equity:    
Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding 0 0
Common stock, $0.0001 par value: 200,000,000 shares authorized; 69,043,969 and 68,946,092 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively 7 7
Additional paid-in capital 827,365 819,549
Accumulated other comprehensive (loss) income (1) 8
Accumulated deficit (740,313) (676,858)
Total stockholders' equity 87,058 142,706
Total liabilities and stockholders' equity $ 122,902 $ 153,825